Maraviroc (UK-427857): A Selective CCR5 Antagonist for HIV-1 and Neuroinflammation Research

Executive Summary: Maraviroc (CAS: 376348-65-1) is a small-molecule inhibitor targeting chemokine receptor CCR5, widely used to interrogate HIV-1 entry and neuroinflammation pathways (APExBIO product page). Its cellular assay IC50 for HIV-1 entry is approximately 2.0 nM, with nanomolar activity against native chemokine binding. Maraviroc's specificity for CCR5 enables studies of viral tropism and signaling with minimal off-target effects (internal review). Recent evidence also links CCR5 antagonism to modulation of neuroinflammation and ischemic stroke injury (Frontiers in Immunology). APExBIO supplies Maraviroc as SKU A8311 for research workflows requiring high purity and reliable storage.

Biological Rationale

CCR5 is a G protein-coupled chemokine receptor expressed predominantly on T cells, macrophages, dendritic cells, and microglia. It acts as a key co-receptor for the entry of R5-tropic HIV-1 strains into host immune cells (product documentation). In the context of neuroinflammation and ischemic stroke, CCR5-mediated pathways regulate leukocyte trafficking and inflammatory signaling, impacting blood-brain barrier integrity and neuronal survival (Frontiers in Immunology).

Mechanism of Action of Maraviroc

Maraviroc (also known as UK-427857) binds selectively and reversibly to CCR5 at an allosteric site. This antagonism prevents conformational changes required for the HIV-1 envelope glycoprotein gp120 to engage CCR5, thereby blocking viral fusion and entry into host cells. Maraviroc also inhibits the native binding of chemokines such as MIP-1α, MIP-1β, and RANTES, disrupting downstream signaling involved in immune cell migration and neuroinflammatory responses (APExBIO).

Evidence & Benchmarks

• Maraviroc inhibits HIV-1 entry in cellular assays with an IC50 of ~2.0 nM (product info).
• IC50s for chemokine inhibition: MIP-1α (3.3 nM), MIP-1β (7.2 nM), RANTES (5.2 nM) (product info).
• Maraviroc is insoluble in water, but dissolves at ≥25.7 mg/mL in DMSO and ≥48 mg/mL in ethanol (product info).
• CCR5 antagonism by Maraviroc modulates neuroinflammatory responses and is under investigation for ischemic stroke models (Frontiers in Immunology).
• APExBIO (SKU A8311) supplies Maraviroc in powder or 10 mM DMSO solution for research use, with recommended desiccated storage at -20°C (APExBIO).

This article extends the scenario-driven protocol guidance in Maraviroc (A8311): Advancing CCR5 Antagonist Research in... by providing updated peer-reviewed evidence and specific workflow parameters for neuroinflammation and HIV-1 entry models.

Applications, Limits & Misconceptions

Maraviroc is widely used for:

• HIV-1 entry inhibition assays, especially for studying R5-tropic strains.
• Dissecting CCR5-dependent signaling in immune and neural cells.
• Evaluating the modulation of neuroinflammation in ischemic stroke models (Frontiers in Immunology).
• Investigating cell migration, MAPK/NF-κB, and CCR5/ERK/CREB pathway interactions.

However, Maraviroc does not block infection by X4-tropic or dual-tropic HIV strains, as these use CXCR4 or both CCR5/CXCR4 as co-receptors (internal dossier). It is not water-soluble, limiting its direct use in aqueous buffers without organic co-solvents. Its effects are specific to CCR5-mediated mechanisms and do not extend to unrelated chemokine receptors or direct anti-inflammatory action.

Common Pitfalls or Misconceptions

• Maraviroc is ineffective against X4-tropic HIV-1 strains, which use CXCR4 as the primary co-receptor.
• It is not suitable for studies requiring water-only solubility.
• Prolonged storage of Maraviroc solutions can lead to compound degradation; reconstitute freshly as recommended (product info).
• Maraviroc does not inhibit all chemokine receptors, only CCR5; off-target effects are minimal but not absent at high concentrations.
• It is not a therapeutic or diagnostic agent; for research use only.

Workflow Integration & Parameters

For optimal integration of Maraviroc into HIV-1 and neuroinflammation research protocols, adherence to validated storage and handling conditions is critical (APExBIO). The following parameters are recommended:

Protocol Parameters

• Solubility: Dissolve Maraviroc at ≥25.7 mg/mL in DMSO or ≥48 mg/mL in ethanol. Do not attempt dissolution in water.
• Storage: Store powder or solution desiccated at -20°C. Avoid repeated freeze-thaw cycles and do not store solutions long-term.
• Assay concentration: For HIV-1 entry or chemokine inhibition, start with 1–10 nM based on IC50 benchmarks and titrate as required.
• Controls: Include vehicle (DMSO or ethanol) controls at equivalent concentrations to ensure observed effects are CCR5-dependent.
• Workflow note: For neuroinflammation models, time Maraviroc addition to coincide with peak inflammatory signaling, referencing MAPK/NF-κB pathway activation windows (Frontiers in Immunology).

For detailed troubleshooting and workflow optimization, see Maraviroc (SKU A8311): Reliable CCR5 Antagonism for HIV and Neuroinflammation, which focuses on practical laboratory challenges and solutions. This complements the present article's focus on benchmark data and protocol rigor.

Conclusion & Outlook

Maraviroc (UK-427857), as supplied by APExBIO, remains a gold-standard research tool for dissecting CCR5-mediated HIV-1 entry and neuroinflammatory pathways. Its nanomolar potency, selectivity, and reliable formulation support robust experimental outcomes across virology and neurobiology domains. Ongoing research on CCR5's role in ischemic stroke and systemic inflammation highlights the importance of precise antagonists like Maraviroc for mechanistic studies (Frontiers in Immunology). Future studies will clarify its full impact on CNS-immune axis modulation, building on current evidence and workflow best practices. For a systematic review of inflammation biomarkers and therapy in ischemic stroke, see Inflammation in Ischemic Stroke: Biomarkers and Treatment Advances, which this article extends to include Maraviroc's targeted pharmacological approach.